Howard I. Scher is the Chief of the Genitourinary Oncology at Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College. He has a depth of experience in clinical trials for novel types of cancer treatment.[1]
Scher earned his BS from Bates College and his MD from New York University School of Medicine before doing his residency at Bellevue Hospital.[2] He married Deborah Ann Lafer in 1989.[3]
Scher has been an investigator at Memorial Sloan Kettering Cancer Center since 1992 and Professor of Medicine at the Weill Cornell Medical College.[4] His areas of research include PI3K, the androgen receptor, HSP90, and immunotherapy.
Scher is on the board of directors at Asterias, a biotechnology company.[5]
Scher was awarded American Association for Cancer Research's 2015 Team Science Award along with Michael E. Jung and Charles Sawyers for their work in the development of enzalutamide.[6] He has also collaborated with Brett Carver and Neal Rosen, both also at MSKCC, on experimental cancer therapeutics for androgen-resistance prostate cancer.[7]
Scher has published over 500 scholarly works.
